塞鲁美替尼
癌症研究
医学
MEK抑制剂
丝状蛋白
癌症
细胞
细胞生长
激酶
波形蛋白
大疱性表皮松解症
药物重新定位
蛋白激酶A
细胞迁移
药品
曲美替尼
皮肤癌
生物
体外
运动性
钙调神经磷酸酶
药理学
细胞培养
肿瘤科
作者
Sonja Dorfer,Roland Zauner,Christina Guttmann‐Gruber,Victoria Reichl,Michael Ablinger,Stefanie Gruner,Julia Illmer,Josefina Piñón Hofbauer,Ulrich Koller,Iris Karina Gratz,Johann Wolfgang Bauer,Verena Wally
标识
DOI:10.1016/j.jid.2025.12.010
摘要
Squamous cell carcinomas arising in patients with recessive dystrophic epidermolysis bullosa are highly aggressive and often cause premature death. Current treatment options are limited, highlighting the need for innovative drug development concepts. Through transcriptome-guided computational drug screening, we identified selumetinib, a MAPK/extracellular signal-regulated kinase inhibitor, as a candidate drug for recessive dystrophic epidermolysis bullosa-associated squamous cell carcinomas. To verify the therapeutic potential of selumetinib against recessive dystrophic epidermolysis bullosa-associated squamous cell carcinomas, we assessed its efficacy in vitro and in vivo. In vitro, selumetinib decreased tumor cell viability, significantly reduced phosphorylation of extracellular signal-regulated kinase, and induced a mesenchymal-to-epithelial phenotypic shift, as indicated by increased E-cadherin and decreased vimentin expression. Functionally, it impaired tumor cell motility and invasion. Moreover, selumetinib significantly decreased PD-L1 and increased major histocompatibility complex class I levels and modulated the expression of immune-related cytokines. In vivo, selumetinib significantly suppressed tumor growth and reduced phosphorylated extracellular signal-regulated kinase levels in xenograft tumors. RNA sequencing identified EGR1 (early growth response protein 1), FOS (fos proto-oncogene), and DUSP6 (dual-specificity phosphatase 6) as candidate biomarkers of treatment response. Selumetinib, identified by computational drug screening, demonstrates efficacy against recessive dystrophic epidermolysis bullosa-associated squamous cell carcinomas in vitro and in vivo, suggesting its potential for clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI